Evidence map›Paper›PMID 27921139›Full record

Trial reportPsychopharmacology2017

Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial.

James D Kean, Jerome Sarris, Andrew Scholey, Richard Silberstein, Luke A Downey, Con Stough

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 7 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 7 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

James D KeanCentre for Human Psychopharmacology, Swinburne University of Technology, PO Box 218 (H24), Hawthorn, VIC, 3122, Australia.
Jerome SarrisCentre for Human Psychopharmacology, Swinburne University of Technology, PO Box 218 (H24), Hawthorn, VIC, 3122, Australia.
Andrew ScholeyCentre for Human Psychopharmacology, Swinburne University of Technology, PO Box 218 (H24), Hawthorn, VIC, 3122, Australia.
Richard SilbersteinCentre for Human Psychopharmacology, Swinburne University of Technology, PO Box 218 (H24), Hawthorn, VIC, 3122, Australia.
Luke A DowneyCentre for Human Psychopharmacology, Swinburne University of Technology, PO Box 218 (H24), Hawthorn, VIC, 3122, Australia.
Con StoughCentre for Human Psychopharmacology, Swinburne University of Technology, PO Box 218 (H24), Hawthorn, VIC, 3122, Australia. cstough@swin.edu.au.
Swinburne University of Technology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study investigated the effects of a marine oil extract (PCSO-524®) on inattention, hyperactivity, mood and cognition in children and adolescents. PCSO-524® is a standardised lipid extract of the New Zealand green-lipped mussel and is an inflammatory modulator that inhibits the 5'-lipoxygenase and cyclooxygenase pathways and decreases concentrations of the pro-inflammatory arachidonic acid (AA).

methodsPCSO-524® or a matched placebo was administered for 14 weeks to 144 participants (123 males/21 females; mean age 8.7 years) with high hyperactivity and inattention in a randomised, double-blind, placebo-controlled study. The primary outcome was the Conners Parent Rating Scale assessing parental reports of behavioural problems. Secondary outcomes assessed changes in cognition and mood.

resultsThe results of the present study did not support the hypothesis that PCSO-524® improves parental reports of hyperactivity, inattention and impulsivity in children ages 6 to 14 years over placebo. Repeated measures ANOVA on post hoc subsample analysis indicated significant improvements in hyperactivity (p = 0.04), attention (p = 0.02), learning (p = 0.05) and probability of ADHD (p = 0.04) with a medium to large average effect size (d = 0.65) in those children who did not meet criteria for combined hyperactivity and inattention. Furthermore, significant improvements in the PCSO-524® group were indicated in a whole sample repeated measures ANCOVA on recognition memory between baseline and week 8 over placebo (p = 0.02, d = 0.56); this difference was not sustained at week 14.

conclusionsThe results presented indicate that PCSO-524® may be beneficial in reducing levels of hyperactivity and inattention in a population of children with clinical and subclinical symptoms of ADHD.

Indexed as

AffectAttentionCognitionDietary SupplementsAdolescentAttention Deficit Disorder with HyperactivityChildDouble-Blind MethodFatty Acids, Omega-3FemaleHumansLipidsMaleOlive OilTreatment OutcomeVitamin EFatty Acids, Omega-3LipidslyprinolOlive OilVitamin EVitaminsADHDAttentionChildrenCognitionGreen-lipped musselHyperactivityMarine oilMoodOmega-3

Identifiers

PMID27921139
PMCPMC5225177
OpenAlexW2560670432

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.